AG James Secures Insulin Price Cap for New Yorkers from Nation’s Two Largest Manufacturers

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • New York AG Letitia James reached agreements with Eli Lilly and Company and Sanofi-Aventis U.S. LLC to resolve an investigation into insulin pricing practices which found that the list prices set by insulin manufacturers have increased dramatically over the past two decades, and make the product unaffordable to many insulin users.
  • Under the terms of the agreements, Lilly and Sanofi will cap the price of insulin at $35 per month for uninsured New Yorkers for the next five years; continue working with national relief agencies to offer free insulin through eligible non-profit clinics in high-need areas; and provide free insulin to the highest-need consumers who are below the poverty line.
  • The companies also agreed to clearly disclose insulin affordability offerings to consumers and provide information regarding how to apply for these offerings, among other things.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cozen O'Connor | Attorney Advertising

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide